Core Scientific entered this earnings report with a high growth story and a stock that had already been under pressure over the past month. The market’s initial reaction was clear, with the share price falling 12.65% to US$18.12 in regular trading after the results.

The main headline is not revenue, which came in at US$164.2 million for the quarter. The focus is on the size of the loss. Core Scientific reported net income from ongoing operations excluding extra items of US$1.08b in the red and basic earnings per share of US$3.32 in the red, placing the balance sheet and funding plan firmly in the spotlight for investors.

Concerned by Core Scientific’s steep reported loss and looking for stocks with stronger financial footing alongside…